
Twelve years of multiples investors have paid for Themis Medicare Ltd, framed against the sector median so the premium or discount is obvious at a glance.
Twelve years of audited numbers for Themis Medicare Ltd, switchable between annual and quarterly views, consolidated or standalone.
Themis Medicare Ltd reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹948.63 Cr and reported EPS of ₹-2.92.
Disclosed business segments at Themis Medicare with their share of revenue and profit, switchable between consolidated and standalone reporting.
Themis Medicare discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Why someone would buy Themis Medicare Ltd, why someone wouldn't, and the quantitative tripwires that would force the call to flip.
Themis Medicare Ltd's investment case rests on 9 positive markers and 10 flagged concerns drawn from the latest reported filings.
Strong promoter confidence with substantial 67.2% holding indicates long-term commitment.
Healthy balance sheet reflected by a low 0.21 debt-to-equity ratio.
Diverse product portfolio spanning multiple therapeutic areas, including critical care.
Long-standing presence since 1952 provides significant industry experience and connections.
Positive 5-year revenue growth of 15.00% demonstrates historical expansion.
Reported significant net loss of -14.2 Cr, with quarterly profit declining -158%.
Latest quarterly sales dropped by -20.70%, indicating substantial revenue contraction.
Poor profitability. negative EPS (-0.98), P/E 0.00, and very low OPM.
Subpar return ratios. ROCE 10.40% and ROE 7.65% are below peers.
Current price significantly below 52-week high, reflecting negative investor sentiment.
Reassess if quarterly profit growth prints below 0% for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Income thesis breaks if the dividend is cut or yield falls below 0.28%.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Themis Medicare Ltd is highlighted for quick read-across.
| Company Name |
|---|
Aarey Drugs & Pharmaceuticals Ltd |
Aarti Drugs Ltd |
Aarti Pharmalabs Ltd |
Ajanta Pharma Ltd |
Akums Drugs & Pharmaceuticals Ltd |
Albert David Ltd |
Alivus Life Sciences Ltd |
Alkem Laboratories Ltd |
Alpa Laboratories Ltd |
Amrutanjan Health Care Ltd |
Alembic Pharmaceuticals Ltd |
Astrazeneca Pharma India Ltd |
Aurobindo Pharma Ltd |
Bafna Pharmaceuticals Ltd |
Bajaj Healthcare Ltd |
Bal Pharma Ltd |
Biocon Ltd |
Biofil Chemicals & Pharmaceuticals Ltd |
Bliss GVS Pharma Ltd |
Blue Jet Healthcare Ltd |
Brooks Laboratories Ltd |
Caplin Point Laboratories Ltd |
Cipla Ltd |
Cohance Lifesciences Ltd |
Concord Biotech Ltd |
Dishman Carbogen Amcis Ltd |
Divis Laboratories Ltd |
Dr Reddys Laboratories Ltd |
Emcure Pharmaceuticals Ltd |
ERIS Lifesciences Ltd |
FDC Ltd |
Gland Pharma Ltd |
Glaxosmithkline Pharmaceuticals Ltd |
Glenmark Pharmaceuticals Ltd |
Granules India Ltd |
Gufic BioSciences Ltd |
Haleos Labs Limited |
Hester Biosciences Ltd |
Hikal Ltd |
Indoco Remedies Ltd |
Ind-Swift Laboratories Ltd |
Innova Captab Ltd |
IOL Chemicals & Pharmaceuticals Ltd |
Ipca Laboratories Ltd |
Jagsonpal Pharmaceuticals Ltd |
J B Chemicals & Pharmaceuticals Ltd |
Jubilant Pharmova Ltd |
Kilitch Drugs (India) Ltd |
Kopran Ltd |
Krebs Biochemicals & Industries Ltd |
Lasa Supergenerics Ltd |
Laurus Labs Ltd |
Lincoln Pharmaceuticals Ltd |
Lupin Ltd |
Lyka Labs Ltd |
Mangalam Drugs and Organics Ltd |
Mankind Pharma Ltd |
Marksans Pharma Ltd |
Medicamen Biotech Ltd |
Medico Remedies Ltd |
Morepen Laboratories Ltd |
Natco Pharma Ltd |
Nectar Lifescience Ltd |
Neuland Laboratories Ltd |
NGL Fine Chem Ltd |
OneSource Specialty Pharma Ltd |
Orchid Pharma Ltd |
Ortin Global Ltd |
Panacea Biotec Ltd |
Pfizer Ltd |
Procter & Gamble Health Ltd |
Piramal Pharma Ltd |
RPG Life Sciences Ltd |
Sai Life Sciences Ltd |
Sanofi India Ltd |
Sanofi Consumer Healthcare India Ltd |
Senores Pharmaceuticals Ltd |
Shilpa Medicare Ltd |
Sigachi Industries Ltd |
SMS Pharmaceuticals Ltd |
Solara Active Pharma Sciences Ltd |
Sun Pharma Advanced Research Company Ltd |
Strides Pharma Science Ltd |
Sun Pharmaceutical Industries Ltd |
Supriya Lifescience Ltd |
Syncom Formulations (India) Ltd |
Themis Medicare LtdCurrent Stock |
Torrent Pharmaceuticals Ltd |
Unichem Laboratories Ltd |
Valiant Laboratories Ltd |
Venus Remedies Ltd |
Vineet Laboratories Ltd |
Viyash Scientific Ltd |
Wanbury Ltd |
Windlas Biotech Ltd |
Wockhardt Ltd |
Zim Laboratories Ltd |
Zydus Lifesciences Ltd |
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Themis Medicare Ltd — derived from the live tape, not yesterday's close.
Themis Medicare Ltd last traded at ₹102.99 with an intraday range of ₹101–₹104.5 — live indicator, pivot and CPR signals below.
Standard pivot — most widely referenced.
| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 111.66 | +8.67 | +8.42% |
| R3 | 108.16 | +5.17 | +5.02% |
| R2 | 106.33 | +3.34 | +3.24% |
| R1 | 104.66 | +1.67 | +1.62% |
| PIVOT | 102.83 | -0.16 | -0.16% |
| CURRENT | 102.99 | — | — |
| S1 | 94.16 | -8.83 | -8.57% |
| S2 | 97.66 | -5.33 | -5.18% |
| S3 | 99.33 | -3.66 | -3.55% |
| S4 | 101.16 | -1.83 | -1.78% |
THEMISMED is trading Above CPR, indicating Bullishness
CPR is Average
Day's range: 101 ~ 103.75
Trading Inside opening range
Daily traded volume and delivery percentage for Themis Medicare Ltd over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Themis Medicare Ltd stood at 51.2% of traded volume, against a 20-day average of 49.0%.
Filings Themis Medicare sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Every dividend, stock split and bonus issue Themis Medicare has declared, sequenced by announce and record date.
Themis Medicare corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
What Themis Medicare Ltd does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Themis Medicare Ltd operates in the Pharmaceuticals industry under the Health Care sector, listed as NSE: THEMISMED, BSE: 530199.

Themis Medicare Limited is a pharmaceutical company with a significant presence in India and international markets. Its core business revolves around the manufacture and sale of pharmaceutical products, encompassing both Active Pharmaceutical Ingredients (APIs) and finished formulations. This broad portfolio allows them to cater to a wide range of therapeutic needs.
The company's product offerings span numerous therapeutic areas, reflecting a diverse and comprehensive approach to pharmaceutical development and distribution. Key therapeutic categories include anti-tuberculosis and anti-malarial medications, addressing significant global health challenges. They also produce formulations for cardiology, pain management, and anti-infectives, demonstrating a focus on common and critical health concerns.
Furthermore, Themis Medicare's product line extends to haematinics (agents that increase red blood cell production), health and nutrition supplements, anaesthetics, gynaecological medications, and orthopedic pharmaceuticals. This extensive range indicates a commitment to providing a wide array of solutions across diverse medical specialties. The inclusion of anti-inflammatory drugs further broadens their reach within the common therapeutic landscape.
Established in 1952 and headquartered in Mumbai, India, Themis Medicare Limited has a long history within the pharmaceutical industry. Initially known as Themis Chemicals, the company rebranded to its current name in 2001, reflecting its evolution and growth. Their long-standing presence in the market suggests a significant level of experience and established industry connections.
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
The current share price of Themis Medicare Ltd (THEMISMED) is ₹102.99. Today, the stock has gained by ₹2.68 (2.67%), trading in a range of ₹101 to ₹104.5. The stock opened at ₹101 with a trading volume of 14,012 shares.
Themis Medicare Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹948.63 crores, P/E ratio of 0.00, ROE of -3.39%, and ROCE of 10.40%. The dividend yield stands at 0.55%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Themis Medicare Ltd (THEMISMED) is ₹151.19, while the 52-week low is ₹64.95. Currently trading at ₹102.99, the stock is 44.1% away from its 52-week low and 31.9% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Themis Medicare Ltd stock at ₹102.99 depends on multiple factors. The stock is currently trading with a P/E ratio of 0.00 and P/B ratio of N/A. Today's performance shows a gain of 2.67%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Themis Medicare Ltd offers a dividend yield of 0.55%, which means for every ₹100 invested at the current price of ₹102.99, you can expect to receive approximately ₹0.55 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Themis Medicare Ltd's key financial metrics include: P/E Ratio: 0.00, P/B Ratio: N/A, ROE: -3.39%, ROCE: 10.40%, Dividend Yield: 0.55%, EPS: ₹-2.92, Book Value: ₹43.74, Debt-to-Equity: 0.21, and Current Ratio: N/A. The company's market cap stands at ₹948.63 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Themis Medicare Ltd stock opened at ₹101 and is currently trading at ₹102.99, showing a gain of ₹2.68 (2.67%). The intraday high is ₹104.5 and low is ₹101. The trading volume stands at 14,012 shares, indicating moderate market participation today.
Themis Medicare Ltd has a Price-to-Earnings (P/E) ratio of 0.00, which means investors are willing to pay ₹0.00 for every ₹1 of earnings. With an EPS of ₹-2.92, this P/E ratio suggests the stock may be undervalued or facing growth challenges. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Themis Medicare Ltd (THEMISMED) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.
Peers, sector trends, screeners and strategy playbooks contextual to this stock.